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11. Introduction
1.1Cell line in oncology research
Cancers are highly complex disease systems that require multi-dimensional research with
cooperation of different disciplines that are far more than the knowledge of a single
researcher. Cancer tissue is composed of a number of tumor cells; the cancer cell is the
building block with highly representative information of the living cancer entity. To detect the
difference morphology and function between tumor cells and normal cells is fundamental for
cancer research. Knowing the characteristic of cancer cell and understanding the cell-drug
interaction is also essential to cancer biological sciences. For this reason, study based on the
cancer cells is a key important part of cancer research.
Cancer cells retain many of the characteristics of the tumor, such as the ability of proliferation,
secretion, invasion and so on. The cells kept functional receptor and organelle same to the
origin resource, although sometimes they change minor features(Hua et al., 1995). It is
reported that the point mutations found in colorectal cancer cell lines rarely arise during in
vitro culture. Therefore, in tumor-derived cell lines, the genetic changes closely resemble
those of the original tumors(Jones et al., 2008).Moreover, tumor cells are considered to be
the first and ideal preclinical drug models and have proven to be valuable experimental
tools(Zakharyants et al., 2017).
Cancer cell lines, as in vitro model, have incomparable advantages. First, cell lines are easy
to obtain. They can be developed in-house, acquired from other laboratories (if there is no
more reliable source) or purchased from a cell bank. Compared with in vivo animal model,
cell care is much simpler than animal management. It means not only less cost but also less
business on space restriction and epidemic prevention.
Ovarian cancer is the leading cause of death from gynecological malignancies. 90% tumors
arising from the ovary are of epithelial origin(Siegel et al., 2013). A lot of ovarian cancer
2studies are based on cell lines, which are translated into clinical trials step by step. For many
decades, cell lines are definitely attractive models in basic and clinical cancer research.
1.1.1 Primary Cell culture
Usually the majority of cells, even tumor cells, will cease proliferation and tend toward death
after a limited number of cell divisions(Hanahan and Weinberg, 2008).Cell culture is a
technique to maintain the cell alive and proliferate, by which the behavior of cells can be
studied independent of whole organism. Primary cell culture is a procedure of making cell
growth under controlled and favorable artificial conditions after obtainment immediately from
tissue. A lot of research centers have many cells by primary culture, although they also
purchase the cell lines from cell banks in the world.
The primary cells are considered to have advantage for certain cancer research (i.e.
chemo-sensitivity and drug-resistance) than the established cell lines since much closer
related to the clinical situation(Kurbacher et al., 2011). Moreover, cell banks are not able to
provide all kinds of cells. For study on the special type of tumor or rare disease, the suitable
cell line is not readily available. In fact, primary tumor cells are widely used in many
laboratories.
All the cells have individual information of short tandem repeat (STR) markers which should
be authenticated at the beginning, recorded internally and monitored regularly. If the primary
cell mixed with each other, there is no chance to compare with any other standard from
outside. Usually, the origin of the tissue should be kept carefully for future identification.
Primary cell culture is a big challenge for every institute in cell management and storage
during the research.
1.1.2 Continuous cell lines
Continuous cell lines are immortalized cell lines with an infinite lifespan. They can be
repeatedly passaged, reliably recovers from cryopreservation and allowed countless
experiments to be performed without restrictions(Ross et al., 2000; Wistuba et al., 1998).The
3HeLa, a famous cervical cancer cell line derived from a Caucasus women Henrietta Lacks,
was the first human cell line, successfully established in 1951(Scherer et al., 1953). As of
2009, it is reported that more than 60,000 scientific articles had been published about
research done on HeLa and that number was increasing steadily at a rate of more than 300
papers each month. Ovarian cancer studies also rely on in vitro cell line research; more than
one hundred human ovarian cancer cell lines, such as OVCAR3, SKOV-3, A2780, PEO6and
so on, have been used for study (Jacob et al., 2014).
Now thousands of cancer cell lines have been established and kept in cell banks worldwide,
including the American Type Culture Collection (ATCC)http://www.atcc.org/(over 14,000 cell
lines), Cell Bank Australia http://www.cellbankaustralia.com/, the German collection of
microorganisms and cell cultures (DSMZ)http://www.dsmz.de/, the European Collection of
Animal Cell Cultures (ECACC) http://www.hpacultures.org.uk/collections/ecacc.jsp (over
1500 cell lines), the Japanese Collection of Research Bioresources
(JCRB)http://cellbank.nibio.go.jp/,National Cell Bank of Iranhttp://ncbi.pasteur.ac.ir/(UKCCCR
guidelines for the use of cell lines in cancer research(2000).(Jacob et al., 2014)
The more continuous cell lines have to be managed, more opportunity to cross contamination
will occur. Due to commercially available for research, it is of great importance to set up an
international standard applicable to all cell lines, in order to ensure that only high-quality
cancer cell lines with an unequivocal molecular identity and source are distributed to the
research community. It is essential to ensure that the cells are authenticated and free from
contamination.
41.2 Cell line misclassification
Cell line cross-contamination and misidentification has become a serious problem ever since
the establishment of the first cell culture lines. (Alston-Roberts et al., 2010; Freedman et al.,
2015; Nims et al., 2010; Sturzl et al., 2013).The term cross-contamination is used here to
indicate misidentification of one cell line by another, rather than contamination by a
microbiological organism.
1.2.1 The status of cell cross-contamination
This problem has been known for over 60 years since 1956. Based on analyses of cell lines
submitted to international cell banks, the incidence of misidentification in 1977 was
16%(Nelson-Rees and Flandermeyer, 1977) and in 1999 was 18%(MacLeod et al., 1999). In
a recent report there are 85.51% of 69 Chinese cell models and 25% of all 380 samples are
misidentified(Ye et al., 2015).
Over thousands of cell lines have been reported to misidentification. The HeLa is one of the
most common cell lines that contaminate other cells(Capes-Davis et al., 2010). It has been
misidentified as cancer cell of breast, esophagus, liver, lung, nasopharynx, oral cavity, ovary,
salivary gland, stomach, and tongue(Ye et al., 2015). Recently, Christopher Korch et al(Korch
et al., 2012) have evaluated fifty-one ovarian cancer lines by STR analysis. They found ten of
them to be redundant, five identified as cervical cancer cells and two cross contamination.
And in NCI-60 cell line panel, result of DNA fingerprinting has demonstrated misidentification
of ovarian cancer cell lines.
Even though many researchers were aware of the problem and sought solutions 40 years
ago(Bubenik, 2000; Drexler et al., 1999; MacLeod et al., 1999; Nelson-Rees and
Flandermeyer, 1977), scientific community has to confront the most compelling quality-control
issue recently. Until the last ten years, the concerted efforts have been made to require the
use of validated cell lines in grants and publications(Lacroix, 2008; Nardone, 2007).
5Using misidentified cell lines has negative implications on the data generated from the study.
Drug-resistant model derived from the false cell line result in misunderstanding the real
mechanism. Incorrect identified cells lead to wrong interpretation of results, further
confusions and even negative effect on clinical practice. Lastly, the papers have had to be
retracted. Thus, cell culture authentication is an obligatory procedure to ensure reliable data
of science.
1.2.2 The methods for cell authentication
There are several molecular methods used for cell authentication over the years. The
following strategies have been performed or are still in use. Chromosomal analysis and
karyotyping are mainly used to distinguish species. Immuno-phenotypic and
immune-cytochemical analysis could help in the characterization of the histological origin of
cell lines used for identification of certain markers(MacLeod and Drexler, 2006; Potash and
Anderson, 2009). Isoenzyme analysis is possible to identify cell lines by analyzing isoenzyme
electrophoresis profiles and comparing migration patterns with specific and known controls.
Multi-locus DNA fingerprint analysis has a clear advantage to differentiate wide variety of
species(Stacey et al., 1992).The methods, mentioned above, are suitable for the laboratory
working not only with human samples. STR profiling are only successful for a single species;
other species will simply fail to amplify(Masters et al., 2001; Yoshino et al., 2006).
61.3Short tandem repeat profiling
Short tandem repeats (STRs), also known as simple sequence repeats (SSRs) or
microsatellites, are short sequences of non-coding DNA of 2-7 base pairs. It is a type of
variable number tandem repeat (VNTR). They account for approximately 3% of total DNA and
are thought to play a role in the chromosome structure. Each STR locus is highly polymorphic
in length with different repeat number reported as calling code (Figure 1).
Figure1. Different repeats of AGAT are shown in the DNA region .The repeat number “7-12” is
the size call code. The repeat number can vary between individual samples. Adapted from
https://www.celllineauthentication.com/what-is-str-profiling-.html
The call codes are used as molecular markers of specific loci of the genome. Microsatellite
loci differ in each person in terms of the number of repetitions in sequence homologues
between individuals. In brief, it is unique for each individual. So STR profile is also considered
as a distinctive genetic fingerprint.
1.3.1 The method of STR
Short tandem repeats loci can be easily simultaneously amplified by PCR using primers
carrying different colored fluorescent tag in a single tube. Usually four or five different colors
are used for fluorescence dye label. All amplicons of STR loci can be separated by
7electrophoresis on a genetic analyzer based on the size (length of DNA) and analyzed using
powerful software comparing with the standard sample. Finally, the repeat number of each
STR is resulted in a series of numerical codes. The codes of STR loci are polymorphic
between each two samples. The precise data, DNA barcode, are able to improve
identification accuracy to the individual level.
STR profiling has been employed at first by forensic analysts since the early 1990s. Now this
method widely used in many laboratories for cell authentication. After constant development,
a great variety of STR kits have been set up by several biotech companies. Due to
requirement from the Combined DNA Index System (CODIS), the sex determining marker
Amelogenin (X,Y) and 13 microsatellite loci (D18S51, D21S11, TH01, D3S1358, FGA, TPOX,
D8S1179, vWA, CSF1PO, D16S539, D7S820, D13S317 and D5S818) are mandatory(Butler,
2006)
Nowadays, some STR markers consist of four or five nucleotides (repeat motif) with length of
few hundred base pairs are selected and used in forensic framework and cell authentication.
For example, 13 CODIS Core STR Loci include the 13 different loci and two Amelogenin as
following figure 2.
Figure 2. Schematic diagram of 15 markers of 13 CODIS core STR Loci on the
choromosome. Adapted from https://en.wikipedia.org/wiki/Combined_DNA_Index_System
8Moreover, each STR kit has its own special microsatellite loci. For example, D2S1338 and
D19S433 are included in AmpFlSTR® Identifiler kit, as well as Penta E and Penta D in
Powerplex® 16 HS kit. Importantly, the usage of commercial kits and automatic sequence
machine makes the STR profiling procedure more rapid and economical. It is primarily for this
reason that STR profiling is recommended for human cell lines (Nims et al., 2010) and
accepted within the legal system for human identity testing (Butler, 2006).
1.3.2 The valuation of STR
This DNA analysis method, STR profiling is extremely sensitive and reproducible. According
to the study of Hughes-Stamm SR(Hughes-Stamm et al., 2011), intact single source DNA in
amounts as low as 62.5 pg can work well in STR profiling. To the degraded DNA sample,
enhanced kit chemistry, increased cycle number and differing cycling conditions contribute to
improvement in performance and result in effective analysis(Mulero et al., 2006). For
example, AmpFlSTR®MiniFiler™ PCR Amplification kits is a good choice for extreme DNA
degradation (≤200 bp) and template amounts > 250 pg with nearly complete typing
success(Hughes-Stamm et al., 2011).
In a study(Masters et al., 2001) of validation of STR profiling under routine conditions, 253
human cell lines from the leading cell libraries and five cancer research institutes worldwide
are evaluated. The result demonstrates that STR profiling achieves to approximately 80%
success rate and can identify the origin of cell lines. STR profiling of cancer cell lines from
different histological origin (i.e. breast cancer, cervical cancer, glioma) between different
centers and different passages indicate relative stability, although cancer cell have more
chromosome aberration. Therefore, STR profiling has recently been recommended as an
international standard technique for human cell authentication(Alston-Roberts et al., 2010;
Masters et al., 2001; Nims et al., 2010).
9Another obvious advantage of STR profiling is that generation a numerical code per sample
make it easy to establish an internal database and online service center. After that, all the
information of STRs is able to be shared with each other and published online. Cells have
individual STR pattern comparable online with suitable data libraries like DSMZ or ATCC.
When searching an online database of STR profiles from cell lines, the user needs to look for
close matches and not just identical matches; most studies would agree that 80% similarity is
an appropriate threshold for declaring a match when comparing cell line profiles(Lorenzi et al.,
2009; Masters et al., 2001). There may also be a significant start-up cost if testing in-house;
in addition to an STR kit, access to methods for DNA extraction, precise quantitation,
fragment analysis and software for STR profile identification is required.
Therefore, STR profiling has recently been recommended as an international standard
technique for human cell authentication.
1.3.3 The Limitation of STR
Although STR profile has been a benchmark for cell line identification, we should pay more
attention to the limitation of this method when using for some tumor cells during passage.
First, in the same cell lines, continuous passage in the culture can result in a genetic drift.
Particularly in cancer cells, genetic alterations appears as loss of heterozygosis, allelic
instability of addition or deletions, which induce changes in STR profiles in some degree
(Kurbacher et al., 2011; Potash and Anderson, 2009; Ross et al.,2000). Alterations of DNA
fingerprinting profiles have been reported for some established hematopoietic cancer cell
lines, during long-term culture. Parson et al. (Parson et al., 2005) found that STR profiling
have limitations in leukemia cell lines with long time culture because of dramatic difference in
marker stability, which will makes cell authentication more complex. In highly unstable cell
lines like HCT-116, the major allele can drift even over the course of a week which might
account for different biological data generated in different laboratories(Narayan, 2004;
Shureiqi et al., 2005). Alterations were so drastic that DNA fingerprinting profiles of cultured
cell lines and parental cells also differed considerably(Parson et al., 2005). Even if
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misidentification of a cell line is ruled out, there remains the possibility that mutations or
rearrangements may alter the phenotype of the cell line between cell passages.
Secondly, mixture of cells may interfere with STR profiling. More than 2 peaks on one STR
marker should be cautious about cross contamination. However, of original tumor tissue or
blood, it is possible that the cell mixture have composed of different cell clones. Mono-clone
tumor cells also may have polyploidy chromosome. These conditions are able to result in
more than two peaks in some special loci, which lead to wrong judgement. Usually, a fewer
markers affect by cell mixture of the same origin less than that of cross contamination.
Third, in cases of extreme degradation samples and/or template amounts less 250 pg, STR
profiling is hard to be achieved with complete information, but mini-STR or Single Nucleotide
Polymorphism (SNP) analysis is a better alternative with more success(Hughes-Stamm et al.,
2011). For good quality and moderately degraded samples in amounts within the
recommended input amounts for PCR, STR profiling would be the most appropriate choice.
It is suggested that cell authentication with STR profile should be carried out regularly and
continuously. Once in doubt, different concentrations and different methods can be used for
re-evaluation.
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1.4 Aim of this study
Cell line is used as a pivotal tool in biological research. Advances research in ovarian cancer
also benefits from the valid ovarian tumor cell lines. But now, the cell line contamination and
misidentification is a big problem. There are many reasons for this problem. For example, the
sample was mismarked or the wrong pipette was used or the cells are contaminated during
incubator. These operational errors can be avoided through standard operating procedures.
However, we would like to know if contamination occurs during cell line preservation in liquid
nitrogen.
STR profile has been recommended to be an international standard for human cell line
authentication by worldwide. Most of the STR profiling studies about the ovarian cancer cells
identification focus on the continuous cell lines. Only few reports pay attention to
authentication of primary ovarian cell culture. But in actual, primary ovarian cells are widely
used in many laboratories. STR profiling have limitations in highly unstable tumor cell lines
with long time culture due to dramatic alternation of microsatellites, and in degradation
samples due to short template for insufficient amplification; in mixture sample due to more
peaks in one loci. All these conditions will make cell authentication more complex. Therefore,
a potential drift of STR markers in primary cancer cell culture is still a problem. Hence, the
aim of this study is to continuously monitor the characteristic of STR profile of primary
epithelial ovarian carcinoma cells with or without multiple times of freeze-thaw cycle. We also
plan to establish our own SOP of STR profiling. The following questions should be
addressed.
1. Does the contamination of cell lines occur during storage in liquid nitrogen phase?
2. Would STR markers do change during the primary culture? And what kind of the
alternation would be happen?
3. Is STR profiling an effective method for cell authentication even in a state of the alternation
of STR markers of primary ovary cancer cell lines?
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2. Materials and methods
2.1 Methods of the contamination tests
First, a new storage tank of 20 liter was aseptically treated and full filled with fresh liquid
nitrogen. And the liquid nitrogen would be added every week to maintain the valid level during
the whole test. Secondly, 4 cyro-vials (2mL) with SKOV3 cells were taken off the lids and put
into the tank. The tank was shaken enough but gently each day in the first three days. After
five days, 21 cryocanes totally with 105 tubes (each with 1mL frozen medium) were drop
deeply immersion into liquid nitrogen in the tank. 30 cryo-vials were sealed tightly and 75
cryo-vials were loosened. (figure3). The loosen means counterclockwise rotation of sealed
cap about 15 degree, which can result the leakage of cryo-vial but the cap is not fall-off.
Finally, at the point of 2 weeks, 4 weeks and 8 weeks respectively after the beginning of the
storage, the medium in 10 sealed tubes and 25 loosen tubes were thawed and cultured in
25mL flask. Each day the flasks were monitored carefully to confirm whether any cell is
growing. If the cells are found, they will be cultured and tested with STR markers.
Figure 3: the top and cross-sectional views of the tank
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2.2 Patient’s information
16 patients diagnosed with primary epithelial ovarian cancer were considered eligible for this
study. During March 2008 to October 2011, they all were treated in the Department of
Gynecology and Obstetrics, University Medical Center Schleswig-Holstein,
Christian-Albrechts University of Kiel, Germany. All procedures performed in this study
involving human participants were in accordance with the ethical standards of the institutional
and national research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards (B372/10 Kiel 2011). Informed consent was
obtained from each patient for the use of the tissue and the blood in this study.
Clinic-pathological data of all enrolled patients were collected from the medical records.
Tumor histological cell type and grade were determined by pathologist and tumor stage by
gynecologic oncologist following the International Federation of Gynecology and Obstetrics
(FIGO) classification(Pecorelli et al., 1999) (Table 1).
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Table 1. Surgical staging classification. FIGO nomenclature (1988)
Stage I Growth limited to the ovaries
Stage Ia Growth limited to one ovary; no ascites present containing malignant cells.
No tumor on the external surface; capsule intact
Stage Ib Growth limited to both ovaries; no ascites present containing malignant cells.
No tumor on the external surfaces; capsules intact
Stage Ic Tumor either Stage Ia or Ib, but with tumor on surface of one or both ovaries,
or with capsule ruptured or with ascites present containing malignant cells or
with positive peritoneal washings
Stage II Growth involving one or both ovaries with pelvic extension
Stage IIa Extension and/or metastases to the uterus and/or tubes
Stage IIb Extension to other pelvic tissues
Stage IIc Tumor either Stage IIa or IIb, but with tumor on surface of one or both ovaries,
or with capsule ruptured, or with ascites present containing malignant cells or
with positive peritoneal washings.
Stage III Tumor involving one or both ovaries with histologically confirmed peritoneal implants
outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver
metastasesequals Stage III. Tumor is limited to the true pelvis, but with histologically proven
malignant extension to small bowel or omentum
Stage IIIa Tumor grossly limited to the true pelvis, with negative nodes, but with
histologically confirmed microscopic seeding of abdominal peritoneal
surfaces, or histologically-proven extension to small bowel or mesentery
Stage IIIb Tumor of one or both ovaries with histologically confirmed implants,
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm
in diameter; nodes are negative
Stage IIIc Peritoneal metastasis beyond the pelvis>2 cm in diameter and/or positive
retroperitoneal or inguinal nodes
Stage IV Growth involving one or both ovaries with distant metastases. If pleural effusion is present,
there must be positive cytology to allot a case to Stage IV. Parenchymal liver metastasis
equals Stage IV
Cited in Pecorelli et al(1999)
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2.3 Materials
2.3.1 Instruments
Description Type Company
Biological safety cabinets Series 9 and 11 Nuaire Inc. USA
Cell culture centrifuge Rotina 48 RC Hettich, Tuttlingen
Cell disrupter Fastprep FP120 Bio 101 Savant instruments Inc.
USA
Centrifuge Universal 16R Hettich, Tuttlingen
Cryo freezing container 5100 Nalgene, Thermo Scientific Inc.
UK
Fluorometer Qubit 2.0 Life technologies corporation, USA
Genetic Analyzer 3130 Applied Biosystems Inc.USA
Ice Machine AF100 Scotsman ice systems S.P.A, Italy
Inverted micorscope Axiovert 25C Carl Zeiss GmbH, Jena
Liquid nitrogen containers GT 140 Air Liquide GmbH, Düsseldorf.
Microcentrifuge 5415R Eppendorf, Hamburg
PCR Workstation CleneCab Herolab GmbH. Wiesloch
Peltier Thermal Cycler PTC-200 MJ reseach Inc. USA
Platform shaker Unimax 1010 Heidolph GmbH. Schwabach
Pipettor Research
(10 μL,100 μL,1 mL)
Eppendorf, Hamburg
Refrigerator(-20°C) Premium Liebherr, Germany
Refrigerator(-80°C) Forma 900 series Thermo Scientific Inc. UK
Spectrophotometer Ultrospec 3000UV/visible Pharmacia Biotech Ltc. England
Steri-Culture CO2 Incubator HEPA class-100 Thermo Scientific Inc. UK
Thermomixer 5436,comfort Eppendorf, Hamburg
Vortex Vortex Genie2 Scientific industries Inc., USA
Water bath 1086 GFL GmbH, Burgwedel
Water Purification System Milli-Q Millipore GmbH, Schwalbach
2.3.2 Consumables
Description Company
Biospherefilter
tips(0.5-20μL,2-100μL,100-1000μL)
Sarstedt, Nümbrecht
Biosphere micro tube (0.5ml and 1.5mL) Sarstedt, Nümbrecht
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Cell culture flasks (25 cm2 and 75cm2) Sarstedt, Nümbrecht
Cell scraper (16cm) Sarstedt, Nümbrecht
Cryovials (2mL) Simport, Canada
Falcons (15mL and 50mL) Sarstedt, Nümbrecht
Filtropur vacuum filtration units (500mL) Sarstedt, Nümbrecht
Multiply PCR plate(96-well) Sarstedt, Nümbrecht
PCR single Cap 8er-softstrips (0.2mL) Biozym Scientific GmbH, Oldendorf
Pipette tips Eppendorf reference , Hamburg
Pipettes (10 μL, 100 μL and 1 mL) Eppendorf reference , Hamburg
Pipettes pasteur (250) Glaswarenfabrik Karl Hecht GmbH,
Sondheim
Powder-free gloves Ansell Ltd,UK
Serological pipette(1mL, 5mL,10mL,25mL and
50mL)
Sarstedt, Nümbrecht
Steriflip vacuum driven filtration system Miniport corporation. USA
2.3.3 Chemicals
Description Company
GeneScan 500LIZ size standard Applied Biosystems
Proteinase K Qiagen
Lysing Matrix A QBIOgene
Polymer POP_7 Applied Biosystems
HiDi-formamide Applied Biosystems
DMSO Sigma Ltd. UK
DNA-Exitus Plus AppliChem
Dulbecco’s-Phosphate Buffered Saline (PBS)
1×
Gibco
Fetal calf serum (FCS) Gibco
2-propanol pure Merck KGaA , Darmstadt
Ethanol pure Merck KGaA , Darmstadt
Water for HPLC TH. Geyer GmbH, Renningen
PRMI 1640 culture medium Biochrom AG, Berlin
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Penicillin and Streptomycin
(10000U/mL:10000ug/mL)
Biochrom AG, Berlin(A2213)
Insulin(bovine) Zn-Salt
In PBS w/o Ca2+ Mg2+
Biochrom AG, Berlin (K3510)
Trypsin0.05%/EDTA solution 0.02% (w/v)
In PBS w/o Ca2+ Mg2+
Biochrom GA, Berlin (L2143)
NaCl (6M)
2.3.4 Medium
Description Composition
Cell culture medium RPMI 1640: 500mL; FCS: 50mL; Insulin: traces;
Penicillin:50000U; Streptomycin:50000ug; L-glutamine: 2mM
Freezing medium Cell culture medium:45mL; DMSO:5mL
2.3.5 Kits
Description Composition company
Gentra® Puregene® Cell kit Cell Lysis Solution Qiagen
Protein Precipitation Solution
DNA Hydration Solution
Rnase A Solution
AmpFlSTR® Identifiler®Plus
PCR Amplification Kit
AmpFlSTR® Identifiler® Plus
Primer Set
Applied Biosystems
AmpFlSTR® Identifiler® Plus
Master Mix
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AmpFlSTR® Identifiler® Plus
Allelic Ladder
AmpFlSTR® Control DNA
9947A
QIAamp® DNA Blood Maxi
Kit
QIAamp Maxi Spin Columns Qiagen
Collection Tubes
QIAGEN Protease
Buffer AL
Buffer AW1
Buffer AW2
Buffer AE
2.3.6 Software
Description version company
Adobe Acrobat Reader Version 9.0 Adobe Systems Inc
Adobe Photoshop CS3 Adobe Systems Inc.
Axio Version 40 V4.7.0.0 Carl Zeiss Imaging solutions GmbH
Date collection software Version 3.0 Applied Biosystems
GeneMapperID software Version 3.2 Applied Biosystems
Microsoft Internet Explorer Version 8.0 Microsoft Corporation
Microsoft office Professional edition
2003
Microsoft Corporation
Microsoft Windows XP professional SP3 Microsoft Corporation
Microsoft Windows Version 2000 with SP3 Microsoft Corporation
MW Snap Version3.0.0.74 Freeware of MirekWojtowicz
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2.4 Methods of study on primary ovary cancer cell lines
2.4.1 Sample collection
2.4.1.1 Blood sample collection
Blood with amount of 10mL was taken from a vein in the forearm of the patient using a
syringe before the operation. The blood samples were restored in -20°C for following DNA
extraction.
2.4.1.2 Tumor tissue and cell collection
Tumor cells were harvested from the tumor specimens referring to the method described by
Kurbacher et al(Kurbacher et al., 2011). and slightly modified by our laboratory. Tumor tissue
from the ovary or omentum were obtained intra-operatively under strict asepsis procedure
and were put into a sterile transport vessel containing supplemented RPMI 1640 (including
10% fetal calf serum, 100 U/mL penicillin, 100μg/mL streptomycin, and 2mM L-glutamine and
traces of insulin). Tumor material would immediately be managed in laminar flow cabinet.
Remove necrotic parts, fats and connective tissue in Petri dish and cut the remaining tissue
into fragments of 5-10mm in diameter. Several pieces of tissue fragment were put into the
sterile tube respectively and kept into -80°C for following DNA extraction. The others were
poured in a 15mL tube with 15 mL of trypsin and would be shaking in a 37°C water bath
lasting for 2 hours. If necessary, 70 µm mesh filter gauze was used to remove undissociated
particles. The tube was centrifugated twice at 200g for 10 mins separately with 10mL of
RPMI1640 and phosphate buffered saline(PBS)in order to remove the dissociation enzymes.
The resultant pellet was re-suspended with RPMI1640 and transferred into 75mL
polypropylene culture flasks with totally amount of 15mL.The culture flasks were closed
tightly and arranged into humidified incubator (37°C and 5% CO2) as soon as possible.
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2.4.2 Cell culture and management
2.4.2.1 Subculture
Periodically, the cells were subcultured with 1:2 or 1:3 split ratio when 75% flask bottom
coverage by the cells. In first, the medium were removed from the culture flasks completely
by suction and added 5mL of 0.25% trypsin-EDTA after washing once by PBS 1×. Then the
flask was put into a humidified incubator for 10minutes to start the trypsinization process,
which stopped by adding 10mL of RPMI 1640 medium into the flasks. The cells would be
managed in complete resuspension by knocking at the outer surface of flask bottom and
pipetting the medium up and down for several times. The whole cancer cells containing
medium were transferred into a 50 mL conical tube and then centrifugated at 200g for 10
mins. After pouring away the supernatants, the cell pallet was treated for subculture, freeze
restorage and DNA extraction. The cells were managed according to the diagram shown in
Figure4.
In order to get a stable recycle of management, a strategy would be adopted when four flasks
of cells in the same passage were reached: one flask for DNA extraction, one flask for freeze
restorage and the remaining two flasks for subculture with 1:2 split ratio resulting in new
generation of four flasks.
2.4.2.2 Monitor the cell
We inspected the culture cells every 2 day for cell growth and microbial infection under an
inverted microscope. Usually we changed the medium twice per week. If cells grow quickly,
the medium would be changed every two days. We had taken photos of cell growth each
passage. If necessary, we checked more frequently and took more pictures for continuous
monitor.
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Figture 4. Flow chart of experiments done in this study. Tumor tissue and blood of 16patients
were used to extract DNA to map STR pattern. Remaining tumor tissues were cultured up to
28 passages. In each passage a part of cells was used to extract DNA in order to map STR
pattern. A further part was cryo conserved and sometimes (2–5 times) re-cultured again.
2.4.2.3 Freezing the cell
The cell pallet was re-suspended with amount of 2-3 mL freezing medium: 90% RPMI
1640+10%DMSO. Aliquots of 1.0 mL was filled into a 2.0mL cryo-vial and then put into a
Cryo-freezing container, which could provide the critical, repeatable -1°C per minute cooling
rate required for successful cell cryopreservation. And within one week they would be
transferred to liquid nitrogen.
2.4.2.4 Thawing the cell
After the cells frozen for a certain time, the cryo-vial was taken out of liquid nitrogen
containers and put into a 37°C water bath for about 1.5 minutes until complete thawing. In
order to reduce toxic effect of the cryo-protectants produced during the thawing process, this
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procedure was performed as quick as possible. The cells would be immediately transferred
into a 75mL flask with 14mL RPMI 1640 medium and cultivated as mentioned above.
2.4.2.5 Labeling the cell
Each passage of the cells was labelled by a serial of P plus number. The first P stands for the
primary passage and the following P means each freeze-thaw cycle. The number behind the
P maps the passage of each reculturing. For example, the label of P10 means the tenth
passage of primary culture. The name of P9P4P2 means the cells primary culture for 9
passages, reculture for 4 passages after first freeze-thaw cycle and then for 2 passages after
the second freeze-thaw cycle.
Therefore, we kept the DNA and frozen cells of each passage. Moreover, the frozen cells
would be thawed and re-cultured in the same way a certain time later. All the cells were
routinely monitored carefully and taken photos at each passage with a unique label name.
2.4.3 DNA extraction
2.4.3.1 DNA from cells
DNA was extracted from each passage of the cell using the GentraPuregene core kit (Qiagen)
according to the manufacturer’s instructions. Thoroughly, the pellet was suspended in the
residual fluid by pipetting up and down. 106–107 cells were transferred into a 1.5 mL
micro-centrifuge tube and centrifuged 5 second at 13,200x rpm. The supernatant was
carefully pipetted out and approximately 200μL residual liquid was left. The tube was
vortexed greatly to re-suspend the cells in the residual supernatant in order to facilitate cell
lysis in the next step. The tube was added with 400μL Cell Lysis Solution and vortexed high
speedily following incubation at 37°C for 5 minutes to lyse the cells completely. Mixed with
2.0μL RNase A Solution, the tube was incubated for another 5 min at 37°C and then
transferred on ice to quickly cool the sample. After adding 133μL Protein Precipitation
Solution, the tube was vortexed vigorously for 20 seconds at high speed. The precipitated
proteins would form a tight pellet after centrifuging 1.5 min at 13,200 rpm. If the protein pellet
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was not tight, redo the centrifugation after another 10 minutes cooling on the ice. The
supernatant was transferred into a clean 1.5 mL microcentrifuge tube. The DNA pellet was
washed by 400μL pure isopropanol and 400μL 70% ethanol separately. The DNA would be
visible as a small white pellet. The supernatant was discarded and the tube was drained.
After adding30-100μL DNA Hydration Solution, the tube was incubated at 65°C for 1 hour to
dissolve the DNA and at room temperature overnight with gentle shaking. Samples could
then be centrifuged briefly and transferred to -20°C for storage.
2.4.3.2 DNA from blood samples
10 mL blood and 500μL QIAGEN Protease was properly mixed into a 50 mL centrifuge tube.
After adding 12 mL Buffer AL, we thoroughly mixed and vigorously shook the tube to yield a
homogenous solution. The tube was incubated at 70°C for 10 min and then 10 mL pure
ethanol was added into the sample and mixed completely. One half of the solution was
carefully transferred onto the QIAamp Maxi column placed in a 50 mL centrifuge tube. The
tube was centrifuged at 1850 x g for 3 min and the filtrate was discarded. The remainder of
the solution was load on the same column with the same manipulation. 5 mL Buffer AW1 was
pipetted carefully to the QIAamp Maxi column without moistening the rim followed with
centrifuge at 3000 x g for 2 min. And then the same procedure was managed with washing by
5 mL Buffer AW2. The QIAamp Maxi column was placed in a clean 50mL centrifuge tube, and
600μL Buffer AE were added directly onto the membrane of the QIAamp Maxi column to
equilibrate to room temperature. After 5 minutes incubation at room temperature, the tube
was centrifuged at 4500 x g (5000 rpm) for 2 min. In order to get maximum concentration, the
eluate solution containing the DNA was reload with the same procedure of incubation and
centrifugation. The DNA samples were restored in aliquots at –20°C.
2.4.3.3 DNA from tumor tissue
At the first day, the restored tissue was put into a clean tube with 4 mL SE buffer and 1 mL
Lysing Matrix mixture. Then the tube was placed on the Fast Prep (FP 120) with the lid locked
tightly. After 30 seconds high-speed vibration for disruption of cell membranes, the entire
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contents were transferred into the new Falcon. After pipetted 25 µl Proteinase K and250 µl
20% SDS, the Falcon was shaking in 37°C warm water overnight.
At the second day, the glass hook was labeled with name and put up with the tick in the
appropriate column.1.5 mL Caps with 70% alcohol were laid out (per Falcon 1 Cap). After
pipetted with 1.4 mL of 6M NaCl, the Falcon was vortexed at high speed for 15 seconds.
The Falcon was centrifuged at 4000 rpm for 15 min at the room temperature. After
centrifugation, the supernatant containing the DNA were transferred into the newly labeled
Falcons. 10 mL of 2-propanol was added and the DNA tangle would gradually formed with
gentle swirl of the tube. This was "fished" with the preparation check from the Falcon. The
check mark with the DNA was several times in the cap with the 70% alcohol dipped
(purification step) and put in a tube to dry. DNA concentration was checked on fluorimeter and
adjusted as needed. The DNA samples were restored at –20°C.
2.4.4 PCR
We used AmpFISTR®Identifiler®Plus PCR Amplification kit (Applied Biosystems) according to
the manufacturer’s prescription. It has been shown to be very robust and to produce highly
reliable and reproducible results even from rather difficult templates(Schwark et al., 2011a;
Schwark et al., 2011b). With 2.5ng per sample, PCR amplification was carried out on a MJ
Research PTC-200 thermal cycler using the following conditions: initiation by 95°C for 11
minutes, then 28 cycles of 95°C for 20 seconds, 59°C for 180 seconds, and a hold at 60°C for
10 minutes following 4°C until further processing.
2.4.5 STR profiling test
2.4.5.1 Electrophoresis
Capillary electrophoresis was performed using POP-7 polymer in a 36 cm capillary tube on
an ABI Prism 3130 Genetic Analyzer under the default conditions (injection time 10s and run
time 1200s) with the following components: 11.7μL HiDi-Formamide, 0.3μL size-standard
LIZ-500 and 0.5μL PCR-product per sample. Prior to fragment analysis, this mix was
25
heat-denatured for 3 min to 95°C and snap-cooled on ice for another 3 min, transferred onto
a plate and placed in the ABI Prism 3130 sequencer.
2.4.5.2 Data analysis
The ABI Prism GenemapperTM Software Version 3.2 was used for data collection and
analyses. The zipped file package Identifiler Plus Analysis Files GMID had been downloaded
from the Support menu of www.appliedbiosystems.com for the STR profiling. The panels&
bins standard of Panel Manager was imported and set with Identifiler_Plus_Panels_v1 and
the size standard with CE_G_IdentifilerDirect_GS500, the analysis method with
Identifiler_Plus_AnalysisMethod_v1.
According to the international nomenclature, the analysis method protocol for STR markers
using PCR-Amplifiler kit includes a serial of standards: (1)Stutter ratio cutoff value in tri-,
tetra-, penta- and hexa- motif is 0.15; (2) The defined mini peak amplitude threshold for each
color is 50RFU(relative fluorescence units) and peak window size is 15 points; (3) The sizing
and genotyping quality between 0.75 to 1.0 is pass and between 0 to 0.25 is low quality
range.
2.4.6 Data interpretation, evaluation and validation
In cases of low profiles samples were re-analyzed using different amounts of template DNA.
Samples showing changes in their STR pattern (e.g. allelic drop out or drop in, allele
imbalances) were retyped also using different amounts of DNA and additionally with the
Powerplex 16 multiplex PCR kit (Promega) which amplified 15 STRs, 13 of them identical to
the Identifiler STRs allowing a second independent check-up of the allelic changes.
2.4.7 Data reliability and reproducibility
To ensure that changes in the allelic pattern were no artifacts due to e.g. low template DNA or
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a bad DNA quality, we reanalyzed every peculiar sample at least two more times as
described in material and methods. Only samples with a reproduced altered STR pattern
were included in further interpretation.
2.4.8 Precautions against contamination
Reliable detection of tissue culture contamination requires strict contamination precautions:
Separation of pre- and post-PCR rooms and the treatment of all laboratory surfaces with
DNA-ExitusPlusTM were done to eliminate possible DNA contaminants. All plastic tips and
tubes were sterilized. Laboratory coats, gloves and masks were mandatory items during
preparation, extraction and amplification and solely used for the different separated steps.
Both extraction and PCR reagent negative controls were employed to every PCR to properly
monitor the occurrence of possible contamination. Additionally, the DNA profiles from every
person working in the DNA laboratory were available for mapping of unexpected STR profiles.
No results were used for further interpretation when negative controls showed any DNA
markers.
2.4.9 Match algorithms
All STR pattern of references (blood or tumour tissue) compared with STR pattern of cell
culture were judged by match algorithms. The match algorithm is derived from similarity score
first reported byLynch M in 1990(Lynch, 1990)
The similarity score (Sxy) is an index of DNA fingerprinting similarity between two profiles of
samples (X and Y), defined as how many fragments they match. The above formula is used
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to calculate similarity score (Sxy) , which correspond to the number of peaks common to both
samples x and y, and Nx means the number of peaks of sample X, and Ny the number of
peaks of the sample Y. The similarity score of 0.80 cutoff value (John R Masters, et al 2000)
are accepted by majority of cell bank centers and institutes. We used ‘‘master algorithm’’:
percent match = number shared alleles/total number of alleles in cell culture samples
profile(Masters et al., 2001). Further we used ‘‘modified master algorithm’’: percent match =
number shared alleles/total number of alleles in blood samples profile. We also used the
‘‘Sorensen-Dice coefficient’’: percent match = number shared alleles*2/(total number of
alleles in cell culture samples profile + total number of alleles in blood samples
profile)(Capes-Davis et al., 2013). Value higher 80 % confirm authentication.
The matching criterion is based on an algorithm that compares the number of shared alleles
between two cell line samples, expressed as a percentage. Cell lines with ≥80% match are
considered to be related; derived from a common ancestry. Cell lines with between a 55% to
80% match require further analysis for authentication of relatedness.
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3. Results
3.1 Results of the contamination tests
105 tubes were thawed on three time points and no cells were found to be growing during the
culture whether the tube cap is sealed or loosen. At the end, all the liquid nitrogen has been
dumped out, the four cryo-vials were found on the bottom of the tank with empty.
3.2 Clinical data
16 patients with epithelial ovarian cancer were enrolled, including 2 papillary carcinoma, 3
endometriod adenocarcinoma, 8 serous cancer (2 serous papillary adenocarcinoma, 2
serous papillary carcinoma,3 serous carcinoma, 1 serousadenocarcinoma), 2
adenocarcinoma, 1 serous borderline tumor. The majority of patients suffered with advanced
ovarian cancer in the FIGO stage: one case with stage IV, ten cases with stage III and four
with stage II; only one case was in the stage I. All sixteen patients were elder than 40 years
with the mean age of 60.87±2.66 years(see table 2).
3.3 Culture information
Tumor cells of four patients were harvested from metastasis lesions on the omentum and of
the remaining 12 cases, half from left and right ovarian solid tumor tissue respectively. Six cell
lines had been growing more than 6 months with the max period of 9 months; the others had
cultured accumulated more than 6 months. The cultures have been passaged 4 to 28 times
and been frozen 2 to 5 times. The detailed information listed in table 2.
All cultured cells showed high complex morphology characteristic with the shape of spindle,
round or irregular polygon (supplemental data Table 5). The cells from the patient No.3, with
the highest passage time of 28 and the highest freeze-thaw cycle of 5 times, revealed a
strong ability to proliferate.
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Table 2. Clinical and cell culture information of 16 patients with epithelial ovarian
cancer
NO. Age
(years)
FIGOstage histology source Max.
passage
time
(n)
Max.
froze time
(n)
1 71 IIb
papillary
carcinoma
left
ovarian 9 2
2 63 IIIc
endometrioid
adenocarcinoma
right
ovarian 5 2
3 57 IIIc
serous papillary
adenocarcinoma
left
ovarian 28 5
4 60 IIc
endometrioid
carcinoma
left
ovarian 4 2
5 72 Ic adenocarcinoma
right
ovarian 14 2
6 66 IIIc
serous papillary
carcinoma
left
ovarian 5 2
7 58 IV
papillary
carcinoma omentum 9 2
8 43 IIIb
serous
borderline tumor
Right
ovarian 6 2
9 55 IIIc
serous papillary
adenocarcinoma
Right
ovarian 7 2
10 75 IIIc
serous
carcinoma omentum 13 2
11 48 IIa
serous
adenocarcinoma
Left
ovarian 15 2
12 68 IIIc
serous
carcinoma omentum 8 2
13 60 IIa
serous papillary
carcinoma
right
ovarian 10 3
14 49 IIIc adenocarcinoma
left
ovarian 14 3
15 49 IIIc
endometrioid
adenocarcinoma
right
ovarian 14 3
16 80 IIIc
serous
carcinoma omentum 21 3
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3.4 DNA samples and STR profiles
DNA from six blood samples (No.1, 2, 9, 10, 14, 15) is missing, whereas the related DNA from
corresponding tumor tissue was available. DNA from tumor tissue is missing only in one case
(No.12), although DNA of corresponding blood was available. Nine patients have both blood
and tissue samples. We got 259 DNA samples including 25 from blood and tissue and 234
from cell cultures. Among them, 24 DNA samples with the same concentration were test twice
in the same condition and 28 DNA samples were detected on three amounts of 1ng, 2.5ng,
5ng. All the STR markers have the comparable results of the original pattern. The cells of
patient No.3 from the 13th to 16th passage were re-evaluated by AmpFlSTR® Identifiler kit
and Powerplex® 16 HS kit. The changes of the DNA codes are confirmed. Also, we have
succeeded in getting the STR fingerprint from a common ovarian cancer cell line SKOV3. All
the STR profiles of samples were listed in table 3.
In general, their cell morphology and their STR profile were stable during different passages
and freeze-thaw cycles. But patient No.4 and patient No.5 show different STR pattern in
blood and corresponding tumor tissue. In tumor tissue of patient No.4 the allele of D5S818
with 13 repeats is missing. In tumor tissue of patient No.5 the alleles of D3S1358 with 19
repeats, of TH01 with 9 repeats, and FGA with 25 repeats is missing. (see table 3).
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Table3.STR profile of different resource of all sixteen patients and SKOV3 cell
Sample satus D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539
SKOV3 NCI-60 14;15 30;31,2 13;14 11;11 14;14 9;9,3 8;11 12;12
SKOV3 Culture
cell 14; 15 30;31;31,2 13; 14 11; 11 14 9;9,3 8; 11 12
NO1 Tumor
tissue 12;13 30;32,2 10;11 11 15;16 6 11;12 9;11
Culture
cell 12;13 30;32,2 10;11 11 15;16 6 11;12 9;11
NO2 Tumor
tissue 12;13 29;31 9;11 11;12 14;18 6;9,3 11;12 11;13
Culture
cell 12;13 29;31 9;11 11;12 14;18 6;9,3 11;12 11;13
NO3 Blood
sample 12;13 30 8;14 10;12 17 6;9,3 10;11 9;13
Original
cell 12;13 30 8;14 10;12 17 6;9,3 10;11 9;13
Culture
cell 12;13 30 8;14 10 17 9.3 10 9;13
NO4. Blood
sample 11;15 28;32,2 8;10 10;12 15 6;9,3 9;13 11
Tumor
tissue 11;15 28;32,2 8;10 10;12 15 6;9,3 9;13 11
Culture
cell 11;15 28;32,2 8;10 10;12 15 6;9,3 9;13 11
NO5 Blood
sample 10;14 30;32,2 8;10 10;12 15;19 6;9 12;14 11
Tumor
tissue 10;14 30;32,2 8;10 10;12 15 6 12;14 11
Culture
cell 10;14 30;32,2 8;10 10;12 15;19 6;9 12;14 11
NO6 Blood
sample 13;14 31,2 12 11 16;17 6;9,3 11;14 11;12
Tumor
tissue 13;14 31,2 12 11 16;17 6;9,3 11;14 11;12
Culture
cell 13;14 31,2 12 11 16;17 6;9,3 11;14 11;12
NO7 Blood
sample 14;15 31;31,2 10;12 10;11 15 9.3 12;14 11
Tumor
tissue 14;15 31;31,2 10;12 10;11 15 9.3 12;14 11
Culture
cell 14;15 31;31,2 10;12 10;11 15 9.3 12;14 11
32
Table3.STR profile of different resource of all sixteen patients and SKOV3 cell
Sample satus D2S1338 D19S433 vWA TPOX D18S51 Amel D5S818 FGA
SKOV3 NCI-60 18;23 14;14,2 18;18 11;11 16;17 X 11:11 24;25
SKOV3 Culture
cell 18;23 14;14,2 17;18 8;11 16;17 X 11 24;25
NO1 Tumor
tissue 17;24 14;14,2 16;18 11 12 X 11;12 22;24
Culture
cell 17;24 14;14,2 16;18 11 12 X 11;12 22;24
NO2 Tumor
tissue 18;25 14,2;15 14;16 8 16 X 10;11 20;26
Culture
cell 18;25 14,2;15 14;16 8 16 X 10;11 20;26
NO3 Blood
sample 22;24 13;14 16;17 8;12 12 X 11;12 24
Original
cell 22;24 13;14 16;17 8;12 12 X 11;12 24
Culture
cell 22;24 13;14 16;17 8 12 X 11;12 24
NO4. Blood
sample 19;20 13 16;18 8 12;15 X 11;13 20;21
Tumor
tissue 19;20 13 16;18 8 12;15 X 11 20;21
Culture
cell 19;20 13 16;18 8 12;15 X 11;13 20;21
NO5 Blood
sample 18;20 14;15 14;17 8;11 14;16 X 11;12 22;25
Tumor
tissue 18;20 14;15 14;17 8;11 14;16 X 11;12 22
Culture
cell 18;20 14;15 14;17 8;11 14;16 X 11;12 22;25
NO6 Blood
sample 20 15;16 16;18 8 14;15 X 12 18;24
Tumor
tissue 20 15;16 16;18 8 14;15 X 12 18;24
Culture
cell 20 15;16 16;18 8 14;15 X 12 18;24
NO7 Blood
sample 20;25 14,2;15 15;16 8;11 14;17 X 12 19;22
Tumor
tissue 20;25 14,2;15 15;16 8;11 14;17 X 12 19;22
Culture
cell 20;25 14,2;15 15;16 8;11 14;17 X 12 19;22
33
Table3.STR profile of different resource of all sixteen patients and SKOV3 cell
Sample satus D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539
NO8 Blood
sample 13;14 30;33,2 10;11 11;12 16;18 7;9,3 8;14 13
Tumor
tissue 13;14 30;33,2 10;11 11;12 16;18 7;9,3 8;14 13
Culture
cell 13;14 30;33,2 10;11 11;12 16;18 7;9,3 8;14 13
NO9. Tumor
tissue 9;14 29;31,2 11;12 10;12 16;17 6;9,3 10.11 12;13
Culture
cell 9;14 29;31,2 11;12 10;12 16;17 6;9,3 10.11 12;13
NO10 Tumor
tissue 13;14 29;30 09;10 11;12 16;17 9.3 8;12 11;13
Culture
cell 13;14 29;30 09;10 11;12 16;17 9.3 8;12 11;13
NO11 Blood
sample 12;14 31,2;32 8;12 10;13 15 9.3 8;12 10;11
Tumor
tissue 12;14 31,2;32 8;12 10;13 15 9.3 8;12 10;11
Culture
cell 12;14 31,2;32 8;12 10;13 15 9.3 8;12 10;11
NO12 Blood
sample 12;15 29 8 10 14;15 9 8;12 11;12
Culture
cell 12;15 29 8 10 14;15 9 8;12 11;12
NO13 Blood
sample 12;14 28;32 8;10 10;12 17 7;8 11;12 11
Tumor
tissue 12;14 28;32 8;10 10;12 17 7;8 11;12 11
Culture
cell 12;14 28;32 8;10 10;12 17 7;8 11;12 11
NO14. Tumor
tissue 12;14 29;30 10;11 11;13 15;17 9;9,3 11;12 12;13
Culture
cell 12;14 29;30 10;11 11;13 15;17 9;9,3 11;12 12;13
NO15 Original
cell 13 28 10 12 15 6 9;14 11;13
Culture
cell 13 28 10 12 15 6 9;14 11;13
NO16 Tumor
tissue 13 28;29 9;10 10;11 18 9.3 10;11 12;14
Culture
cell 13 28;29 9;10 10;11 18 9.3 10;11 12;14
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Table3.STR profile of different resource of all sixteen patients and SKOV3 cell
Sample satus D2S1338 D19S433 vWA TPOX D18S51 Amel D5S818 FGA
NO8 Blood
sample 17;18 15;16 17;18 8 16;18 X 12;13 23;24
Tumor
tissue 17;18 15;16 17;18 8 16;18 X 12;13 23;24
Culture
cell 17;18 15;16 17;18 8 16;18 X 12;13 23;24
NO9. Tumor
tissue 17;18 13;14 14;16 8;11 14 X 11;13 20;25
Culture
cell 17;18 13;14 14;16 8;11 14 X 11;13 20;25
NO10 Tumor
tissue 17;25 14;15 16;17 8 16;20 X 12 20;22
Culture
cell 17;25 14;15 16;17 8 16;20 X 12 20;22
NO11 Blood
sample 17 13;14 14;17 8;9 15;22 X 11;12 21;22
Tumor
tissue 17 13;14 14;17 8;9 15;22 X 11;12 21;22
Culture
cell 17 13;14 14;17 8;9 15;22 X 11;12 21;22
NO12 Blood
sample 20;24 14;15 17;18 8 12;16 X 11;12 20;25
Culture
cell 20;24 14;15 17;18 8 12;16 X 11;12 20;25
NO13 Blood
sample 17;20 14 17 8;11 13;17 X 11 20;23
Tumor
tissue 17;20 14 17 8;11 13;17 X 11 20;23
Culture
cell 17;20 14 17 8;11 13;17 X 11 20;23
NO14. Tumor
tissue 23 14;15 16;18 8;10 13;16 X 11;13 23
Culture
cell 23 14;15 16;18 8;10 13;16 X 11;13 23
NO15 Original
cell 17;24 14 18;19 8;11 13;14 X 11;14 19;21
Culture
cell 17;24 14 18;19 8;11 13;14 X 11;14 19;21
NO16 Tumor
tissue 24;25 15;16 17;19 8 12;18 X 11;13 22
Culture
cell 24;25 15;16 17;19 8 12;18 X 11;13 22
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3.5 STR shift as well as morphological transformation occurs
simultaneously
After cryo conservation when tumor tissue was prepared for cell culturing first, re-cultured
cells of patient No.3 began to change their morphology with the 14th passage (figure 4). New
compact small cells appear with apparently different morphology from the original cells of
spindle shape. At the beginning, the new small compact cells emerged in crevice of original
cells with high mobility and proliferated rapidly once taken root to the flask. Cubical cells
growth in cluster. Step by step, the new kind of cells fully covers the bottom of the flask taking
place of the parental cells. Two passages later, the alleles in four STR markers (CSF1PO,
TH01 ,D13S317, TPOX, located on 4 different chromosomes) drop out with gradually
shortening of the height of the one remaining peak until finally signals left completely (Figure4;
Table 4). Cells origin from second cryo conservation after the seventh passage of patient No.
3 change their morphology and STR profile after further four passages in the same manner.
The morphological transformation and STR shift occurs simultaneously. These two series of
cell-cultures from patient No.3 change the morphologic type after about 92 with the initial
freeze-thaw cycle and 84 days with a further freeze-thaw cycles (Table 4). Further re-cultured
cells of patient No. 3 after cryo conservation of the sixth, eighth, and eleventh passage do not
change morphology and STR pattern.
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Figure.4. Morphology and STR pattern changing of patient No.3. Above are images of raising
primary cell culture passages from patient No. 3 from left to right. In a column among are STR
marker peaks of CSF1PO, TH01, D13S317, and TPOX from above to below. Numbers in
squares are for the count of repeats in a STR marker. The arrows in cell culture images mark
different kind of morphology. The arrows in STR graphs mark the disappeared alleles beyond
passage14.
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Table 4 Scheme of cell culturing and cryo conservation of tumor tissue origin patient No. 3.
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P5
P6 (12) ++ -
P7 (10) ++ - P7 P7
P7P2 (13) na - P7P2b (06) na -
P7P3 (10) ++ - P7P3b (08) na -
P7P4 (11) ++ - P7P4b (13) na -
P7P5 (25) na - P7P5b (13) ++ -
P7P6 (27) +- + P7P6b (29) na -
P7P7 (13) +- + P7P7b (29) na -
P7P8 (15) +- +
P8 (07) ++ -
P9 (07) ++ - P9
P9P2 (07) na -
P9P3 (10) ++ -
P9P4 (15) ++ -
P9P5 (16) ++ -
P10 (07) ++ -
P11 (07) ++ -
P12 (11) ++ - P12
P12P2 (14) ++ -
P12P3 (07) ++ -
P12P4 (18) ++ -
P12P5 (13) ++ -
P13 (17) ++ -
P14 (20) ++ +/-
P15 (16) ++ +
P16 (13) +- +
P17 (07) +- +
P18 (09) +- +
P19 (06) +- +
P20 (14) +- +
P21 (11) +- +
P22 (11) +- +
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In a triple column the passages of cell culture are listed including the duration in
days(parenthesis) of flask culturing. The arrows map cryo conservation in liquid nitrogen by
freezing and thawing procedure of a passage. The descriptions give number of primary
passage following the first P. The number behind the next P map the passage after
reculturing. “++” map the pattern of STR marker CSF1PO, TH01, D13S317, and TPOX with
both alleles; whereas “+-“represents a loss of one Allele. A positive sign (+) maps a compact
small morphology of cultured cells, whereas a negative sign (-) is standing for cells of spindle
shape.
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4. Discussion
4.1 Cell cross-contamination do not occur during liquid nitrogen
phase
Cell contamination and misidentification is considered as a common and quality-control
problem (Roberts et al., 2010). However, the reason is not deeply studied. Few researchers
have focused on the cell preservation solution and equipment. It is an interesting question
that whether the contaminated liquid nitrogen will transfer the cells to other tubes in the same
storage tank, even the defective cryo-vials. But in our tests, we do not find this type of
cross-contamination. The results show the cell contamination is more likely occurred outside
of the cell preservation process. As is known to all, the simplest form of misidentification was
mislabeling of cell line (Huang et al., 2017). We have to remind of the standard operating
procedure. Of course, this does not conflict with STR method for cell identification.
4.2 Feasibility of STR profiling during primary ovarian cancer cell
cultures
STR profiling is a high sensitive method to obtain individual information of DNA fingerprint. In
this study, we have got complete and valid STR profile from 94.98% (246/259) of samples,
which is higher than 80% success ratio reported by John R. Masters et al(Masters et al.,
2001). Usually, DNA extracted from cell cultures is intact and sufficient for STR testing.
According to Hughes-Stamm SR(Hughes-Stamm et al., 2011), intact single source DNA in
amounts as low as 62.5pg can work well. Even for extremely degraded samples (<200 bp),
STR genotyping can achieved 100% with amounts of ≥1ng. From human cancer cells in
culture, rather than forensic samples, the quantity and quality of DNA specimens usually are
enough for STR profiling.
Due to high repeatability, STR profiling test is quite stable with the standard procedure. STR
patterns of the same specimen, even repeated in different concentration range,
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are consistent with each other. In our study, 28 DNA samples detected on three amounts of
1ng, 2.5ng, 5ng have the results of the same pattern, since only more stutters have been
found in the group of the highest concentration, which do not interfere with the judgement.
Also, the data of the same specimen using different kits are identical with each other on the
same locus. The alternation of STR markers in patient No.3 among 13 loci of CODIS is
confirmed by two STR-PCR kits respectively. We successfully have obtained the STR profiles
from blood, tumor and cell culture. The data of the same patient from three resources is
comparable. Moreover, we have succeeded in getting the STR fingerprint of SKOV3 cell lines
and comparing with the standard pattern on the web (DSMZ; https://www.dmsz.com).
4.3 STR profile does change during the primary ovarian cancer cell
culture
According to our study, STR profile of primary ovarian cancer cell line definitely does change
during in vitro management, although not often.
While authenticated, this could be proved in one marker of patient No.4 (D5S818) between
blood and tumor tissue, in three markers of patient No.5 (D3S1358, TH01, and FGA) between
blood and tumor tissue. All STR profiles of primary culture passages of Patient No.4 and No.5
are congruent with the STR profile detected from corresponding blood. Perhaps the change
of STR markers between the tumor cells and blood cells is because of some tumor cells with
culturing advantages, however this phenomenon most likely result from allelic losses.
Alteration of STR pattern occurred in primary cell culturing of patient No.3 only, although the
other 15 primary ovarian cell lines had maintained a stable STR pattern among more than 6
months with continuous or accumulated growth undergoing several times of freeze-thaw
cycle. Although primary ovarian cancer cell undergo expand chromosomal rearrangements
resulting in heterogeneous karyotypes in general, the STR pattern of a primary cell culture
seems relatively stable after many passages, freezing and thawing procedures. However, the
changes of STR-pattern we could detect were the loss of alleles only. Simultaneously, one of
peaks in four markers (CSF1PO, TH01, TPOX, and D13S317) disappeared. Due to identical
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changes in primary cell culturing of patient No.3 before and after further cryo conservation, a
mutual basis in form of some clonal cells with the detected allelic loss, divided in frozen
procedure and further passages is very likely. We never recognized a new allele deviate from
original number of repetitive motives in STR positions. With respect to loss of heterocygocity
(LOH) in ovarian cancer, many researches investigate some specific region of chromosome 3,
13, 17 which are related to carcinogenesis and progression(Byrom et al., 2004; Garcia et al.,
2000; Plisiecka-Halasa et al., 2008). But STR markers, adopted by forensic framework,
have few data of LOH or mutation frequency in ovarian cancer. In our results, LOH in both
tumor tissue and cell culture has involved in 8 STR loci. We have not computed the frequency
due to fewer samples. Theoretically, loss of heterozygosity will increase the difficulty of cell
identification because of more single allelic peaks existence. The detected losses of alleles
by AmpFlSTR® Identifiler® Plus kit is sufficient to judge authentication similarity when four
alleles lost(Lynch, 1990; Masters et al., 2001). Thus, we can say the cells with alteration of
STR markers before and after the change are the same origin.
In the present experiment, we also found that the peak dropout process is continuous and
related to the proportion of the changed cells (figure 4). The certain cell clone will survive
under selection pressure while freeze-thaw cycle and culture environment. In contrast to the
loss of heterozygosity, microsatellite instability(Huang et al., 2017), result in the occurrence of
new alleles brought about by mismatch repair deficiency. In study of Parson et al(Parson et
al., 2005) leukemia cell lines, more complex shift of STR markers in every passage, occur
with deletion and addition of allele, which bring about obviously different profile of STR loci.
And Shilpa V et al reported that a relatively high percentage (> 60%) of MSI in 102 ovarian
cancer patients(S V et al., 2014). It is generally accepted, that replication slippages the major
mechanism causing new mutations in microsatellites (Brinkmann et al., 1998; Levinson and
Gutman, 1987). This phenomenon is not given in culturing of epithelial ovarian cancer cells in
our study. Thus, the reliability of authentication by STR profiling is higher in primary ovarian
cancer cell culture than in leukemia cell lines, because new additional alleles are missing in
primary ovarian cancer cell culture as our study demonstrate.
Continuous monitor in culture may be a helpful solution, especially those with varying
characteristics. Interestingly all the cells from patient No.3 would appear to, whether now to
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be frozen or passaging, change the growth pattern and STR profile when in vitro cultured with
amount to 4-6 months. The developing tendency of clonal homogeneity will potentially result
in occurrence of a new cell line.
4.4 STR profiling is a valid method for cell authentication
Usually, during the careful monitor of cell culture, the cross contamination would be found
with the transformation of cell growth. There were reported, that during culture, the BrCa5
cells had transformed spontaneously from fibroblastic to epithelial form and in the case of
HBC cells with rounded shape and floating growth changed to multilayer rapid
growth(Benjamin and Pinkerton, 1976; Nelson-Rees and Flandermeyer, 1977). Both of them
were confirmed with contamination. However, in our study about the patient No.3, the cells
change the growth type similar as described above. At last, STR profiling identified the
alternation of DNA fingerprint rather than cross contamination. When morphological changes
of cell growth is doubt whether the occurrence of cell contamination, we should draw a clear
conclusion by checking STR markers.
With respect to LOH in ovarian cancer, many researches investigate BRCA and TP53 gene
and some specific region of chromosome 3, 13, 17 most on the coding sequence, which are
related to carcinogenesis and progression(Byrom et al., 2004; Garcia et al., 2000;
Plisiecka-Halasa et al., 2008). But STR markers, adopted by forensic framework, have few
data of LOH or mutation frequency in ovarian cancer. In our results, LOH in both tumor tissue
and cell culture has involved in eight STR loci. Due to the small number of samples, it is
impossible to compute the frequency of LOHs. Theoretically, loss of heterozygosity will
increase the difficulty of cell identification because of the existence of more single allelic
peaks.
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4.5 Match algorithms of STR profiles
According the match algorithm derived from similarity score, the match score between the
blood, tumor and cells in our study is higher 80% and confirm authentication. It is high risk
only testing a small number of loci. Interestingly, the bile duct cancer cell line HCCC-9810
and degenerative lung cancer Calu-6 exhibited 88.9% match in the ATCC database (9-loci),
indicating that they were from the same origin. However, when using 21-loci to compare
these two cell lines with the same algorithm, the percent match was only 48.2%, indicating
that these two cell lines were different(Huang et al., 2017).Thus, more markers are
recommended to be checked for STR profiles in cell authentication.
44
4.6 STR profiling is an economic tool for cell authentication
Nowadays, STR profiling is more convenient than before because the different commercial
PCR-STR kits are available from many biological companies. Our experiences support the
opinion that STR profiling can be achieved in the laboratory with routine condition:
conventional PCR machine, DNA sequencers and analysis software. In generally, POP_4
(4% polymer solution with 8 M urea and 5% pyrrolidinone) is specifically formulated for use in
microsatellite analysis. According the introduction of products, POP_7 is also suitable for
fragment and sequencing with characteristic of faster electrophoresis than POP_4. After this
study, we have successfully set up our own SOPs of STR test system using POP_7 on the
ABI 3130 sequencer. It takes only several hours for a batch of operations and dozens of Euro
for each sample. In order to improve the ability of cell differentiation, more loci have been
added to the standard kit. For example, from the beginning there are only 4-7 STR loci
available and now 16 STR loci are used. Recently, 26 STR loci have been evaluated showing
more identification power(Hill et al., 2009). Therefore, balance must be considered between
the number of the loci and the percentage of the match threshold. In a word, STR profiling
has become the first choice for cell lines identification.
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5. Conclusions
Ovarian cancer is the most lethal gynecological malignancy with an overall 5-year survival
rate of approximately 50%. In order to understand occurrence and development of ovarian
cancer, primary ovarian cancer cells, as well as continuous cell lines, are used in many
research centers as an invaluable tool for basic, discovery-driven cancer research.
Misidentification and cross-contamination of cells have hindered research efforts. We need to
pay attention at many levels. However, based on our preliminary test, the contamination of
cell lines during the liquid nitrogen phase does not occur.
Moreover, it is still unclear that genetic changes have an influence on the characterization of
ovarian cancer cell lines and the ability of STR profiles to cell authentication. Based on our
study, it is showed that STR profile of primary ovarian cancer cell line can vary during in vitro
culture, but only detectable with allelic losses. STR-Profiling is necessary and the changes in
profile are more or less negligible and could be compensating by number of tested STR-sites
we used. The balance should be addressed between the number of STR markers tested and
the cutoff value of similarity score.
As a time-dependent observation, the shortcoming of our research should be noticed. First,
less DNA samples in some patients due to low cell proliferation lighten theoretical stringency.
Secondly, we do not test why the eight alleles drop out and how they have effects on the
growth characteristic of the cell. In addition, we suggest that each laboratory should not only
establish the individual STR database of the primary and continuous cell lines used, but also
periodically recheck and update their information. The internal action of self-surveillance
mechanism, as well as the external requirement from journals and funds, will be of great
benefit to eliminate scientific misrepresentation due to cell misidentification.
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7.Appendices
Table.5 The growth characteristic of primary cell culture from all sixteen patients
No.1 No.2
No.4 No.5 No.6
No.7 No.8 No.9
No.10 No.11 No.12
No.13 No.14 No.15
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No.16 No.3(before change) No.3(after change)
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Table 6 Similarity score between certain samples using four conference standards
Conference
standard
Number
of STR
loci
Similarity score
NO.3
(pre-change
:post-change)
NO.5blood
: NO.5tissue
NO.2 cell
:NO.8 cell
NO.9 cell :
NO.3 blood
UK early
standard(1)
6 0.941 0.909 0.454 0.300
DSMZ(2) 9 0.867 0.933 0.413 0.647
CODIS(3) 13 0.904 0.916 0.458 0.489
AmpFlSTR
identifier(4)
16 0.898 0.909 0.428 0.491
(1)UK early standard:vWA, D8S1179, D21S11, D18S51, TH01, FGA
(2)DSMZ:Amel, CSF1PO,D13S317,D16S539,D5S818,D7S820,TH01,TPOX, vWA
(3)CODIS: D3S1358,TPOX, CSF1PO, D5S818, D7S820, TH01,FGA, vWA, D13S317,
D8S1179, D21S11,D18S51,D16S539, Amel
(4)AmpFlSTR identifier: D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317,
D16S539, D2S1338, D19S433, vWA, TPOX, D18S51, Amel, D5S818, FGA
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